Bone Health Status of Children with Spinal Muscular Atrophy
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Spinal muscular atrophy (SMA) is a group of rare, inherited neuromuscular disorders. Bone health is often a neglected issue in children with SMA. This study aimed to evaluate the bone health status of children with SMA in Hong Kong. Methods: This retrospective study included children with SMA who were managed in the Neuromuscular Disorder Clinics of 2 quaternary centers in Hong Kong. Bone health status was assessed by fracture history, bone mineral density (BMD) measured by dual energy X-ray absorptiometry, and serum 25-hydroxy-vitamin D (25[OH]D) level. Results: Thirty-two children were included (males, 12). The median age was 10.8 years. BMD assessments were performed in 17 patients (SMA type 1=2, type 2=8, type 3=7). Low BMD was observed in 16 out of 17 patients. Four had a history of long bone fractures and were started on bisphosphonates. SMA types, age at last visit, sex, ambulation, and 25(OH)D level were not associated with fracture history or BMD Z-scores. Only one fulfilled the 2019 International Society for Clinical Densitometry (ISCD) pediatric definition of osteoporosis, with both low BMD and a history of clinically significant fracture. Conclusions: Children with SMA on disease-modifying treatments commonly had Low BMD and a history of fractures, but osteoporosis was uncommon according to the 2019 ISCD pediatric definition. A special definition of osteoporosis may be needed for this high-risk group.
Abstract
Background: Spinal muscular atrophy (SMA) is a group of rare, inherited neuromuscular disorders. Bone health is often a neglected issue in children with SMA. This study aimed to evaluate the bone health status of children with SMA in Hong Kong. Methods: This retrospective study included children with SMA who were managed in the Neuromuscular Disorder Clinics of 2 quaternary centers in Hong Kong. Bone health status was assessed by fracture history, bone mineral density (BMD) measured by dual energy X-ray absorptiometry, and serum 25-hydroxy-vitamin D (25[OH]D) level. Results: Thirty-two children were included (males, 12). The median age was 10.8 years. BMD assessments were performed in 17 patients (SMA type 1=2, type 2=8, type 3=7). Low BMD was observed in 16 out of 17 patients. Four had a history of long bone fractures and were started on bisphosphonates. SMA types, age at last visit, sex, ambulation, and 25(OH)D level were not associated with fracture history or BMD Z-scores. Only one fulfilled the 2019 International Society for Clinical Densitometry (ISCD) pediatric definition of osteoporosis, with both low BMD and a history of clinically significant fracture. Conclusions: Children with SMA on disease-modifying treatments commonly had Low BMD and a history of fractures, but osteoporosis was uncommon according to the 2019 ISCD pediatric definition. A special definition of osteoporosis may be needed for this high-risk group.
참고문헌 (22)
- Mercuri E, "Childhood spinal muscular atrophy : controversies and challenges", Lancet Neurol, 11, pp.443~452 (2012)[DOI]
- Vai S, "Bone and spinal muscular atrophy", Bone, 79, pp.116~120 (2015)[DOI]
- Wasserman HM, "Low bone mineral density and fractures are highly prevalent in pediatric patients with spinal muscular atrophy regardless of disease severity", Neuromuscul Disord, 27, pp.331~337 (2017)[DOI]
- Mercuri E, "Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care", Neuromuscul Disord, 28, pp.103~115 (2018)[DOI]
- Schorling DC, "Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care", J Neuromuscul Dis, 7, pp.1~13 (2020)[DOI]
- Pierzchlewicz K, "Spinal muscular atrophy : the use of functional motor scales in the era of disease-modifying treatment", Child Neurol Open, 8 (2021)[DOI]
- Mueske NM, "Reliability of lateral distal femur dual-energy X-ray absorptiometry measures", J Clin Densitom, 17, pp.522~527 (2014)[DOI]
- Weber DR, "The utility of DXA assessment at the forearm, proximal femur, and lateral distal femur, and vertebral fracture assessment in the pediatric population: 2019 ISCD official position", J Clin Densitom, 22, pp.567~589 (2019)[DOI]
- Zemel BS, "Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children : results of the bone mineral density in childhood study", J Clin Endocrinol Metab, 96, pp.3160~3169 (2011)[DOI]
- Shuhart CR, "Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics", J Clin Densitom, 22, pp.453~471 (2019)[DOI]
- Peng X, "Bone mineral density and its influencing factors in Chinese children with spinal muscular atrophy types 2 and 3", BMC Musculoskelet Disord, 22, pp.729~ (2021)[DOI]
- Kinali M, "Bone mineral density in a paediatric spinal muscular atrophy population", Neuropediatrics, 35, pp.325~328 (2004)[DOI]
- Aton J, "Vitamin D intake is inadequate in spinal muscular atrophy type I cohort : correlations with bone health", J Child Neurol, 29, pp.374~380 (2014)[DOI]
- Baranello G, "Evolution of bone mineral density, bone metabolism and fragility fractures in Spinal Muscular Atrophy (SMA) types 2 and 3", Neuromuscul Disord, 29, pp.525~532 (2019)[DOI]
- Veilleux LN, "Muscle-bone interactions in pediatric bone diseases", Curr Osteoporos Rep, 15, pp.425~432 (2017)[DOI]
- Khatri IA, "Low bone mineral density in spinal muscular atrophy", J Clin Neuromuscul Dis, 10, pp.11~17 (2008)[DOI]
- Shanmugarajan S, "Congenital bone fractures in spinal muscular atrophy : functional role for SMN protein in bone remodeling", J Child Neurol, 22, pp.967~973 (2007)[DOI]
- Vermeren M, "Osteoclast stimulation factor 1(Ostf1)KNOCKOUT increases trabecular bone mass in mice", Mamm Genome, 28, pp.498~514 (2017)[DOI]
- Shanmugarajan S, "Bone loss in survival motor neuron(Smn(-", -)SMN2)genetic mouse model of spinal muscular atrophy, 2009, pp.219, 52~60
- Nasomyont N, "Intravenous bisphosphonate therapy in children with spinal muscular atrophy", Osteoporos Int, 31, pp.995~1000 (2020)[DOI]
- Tung JY, "Bone microarchitectural alterations in boys with Duchenne muscular dystrophy on long-term glucocorticoid treatment", J Bone Miner Metab, 39, pp.606~611 (2021)[DOI]
- Tian C, "Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy", Neuromuscul Disord, 26, pp.760~767 (2016)[DOI]